Abu Dhabi – Asdaf News:
G42 Healthcare’s Somalogic Proteomics Laboratory is currently the first accredited Proteomics site in EMEA thanks to the SomaScan Discovery Assay.
This accomplishment follows the recent launch of M42, a first-of-its-kind, tech-enabled, integrated healthcare company made possible by the union of G42 Healthcare and Mubadala Health. M42 combines the world-class patient services and cutting-edge facilities of Mubadala Health with the exceptional medical and data-centric technologies of G42 Healthcare to deliver the highest level of individualized, precise, and preventative care.
The coveted milestone builds on the recent partnership between G42 Healthcare – a leading Abu Dhabi-based AI health-tech company, and SomaLogic, a leader in data-driven proteomics, which is the study of the interactions, function, composition, and structures of proteins and their cellular activities.
G42 Healthcare earned the certification upon passing the SomaSignal® Assay performance requirements, spearheaded by SomaLogic. The recently-earned certification equips G42 Healthcare to support and drive clinical decisions as well as future development of tests using genomic, proteomic and clinical characteristics. Both teams are committed to develop future protein signatures for the people of the UAE, including validating tests that can predict cardiovascular risk 4 years ahead of time, which will have huge impact on personalized treatments and reduce the long-term cost to healthcare providers.
The SomaScan® platform was designed as a universal platform that can be applied across research and discovery, translational research, biopharmaceutical development, and clinical applications.
G42 Healthcare and SomaLogic also plan to collaborate on business development, strategy, and applications for the life sciences and healthcare markets, including championing SomaSignal® tests in UAE, Saudi Arabia, GCC and selected broader territories.
